Clinical application of adult stem cells for therapy for cardiac disease.

Abstract:

INTRODUCTION:Cardiovascular disease is a major cause of death worldwide. Different medical and surgical therapeutic options are well established, but a significant number of patients are not amenable to standard therapeutic options. Cell-based therapies after clinical application have shown different results in recent years. Here, we are giving a comprehensive overview on major available clinical data regarding cell therapy. BACKGROUND:Cell-based therapies and tissue engineering provide new promising platforms to develop upcoming therapeutic options. Initial clinical trials were able to generate promising results. A variety of different stem cell types have been used for the clinical application. Different adult cardiac stem cells and progenitor cells, including mesenchymal, CD34(+) and CD133(+) autologous human bone marrow-derived stem cells (BMCs), human myoblasts, and peripheral blood-derived stem and progenitor cells (PBSCs) have been used for the therapy for end-stage heart failure. Future experiments will show the importance of novel cell populations and clarify the mechanism causing cell therapy-mediated observed effects. CONCLUSION:Several clinical trials have reported on sole therapy, as well as combined application of autologous adult stem cells with conventional revascularization. The reported promising findings encourage further research in the field of the translational research.

journal_name

Cardiovasc Ther

authors

Ghodsizad A,Ruhparwar A,Bordel V,Mirsaidighazi E,Klein HM,Koerner MM,Karck M,El-Banayosy A

doi

10.1111/1755-5922.12032

subject

Has Abstract

pub_date

2013-12-01 00:00:00

pages

323-34

issue

6

eissn

1755-5914

issn

1755-5922

journal_volume

31

pub_type

杂志文章,评审
  • Secondary prevention in concurrent coronary artery, cerebrovascular, and chronic kidney disease: focus on pharmacological therapy.

    abstract::Patients with coronary artery disease (CAD) commonly have varying degrees of coexisting cerebrovascular disease (CVD) and chronic kidney disease (CKD), and proper management is complicated partly because of a lack of unifying guidelines. The aim of this article is to review the current literature and propose the optim...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2009.00087.x

    authors: Notaro LA,Usman MH,Burke JF,Siddiqui A,Superdock KR,Ezekowitz MD

    更新日期:2009-10-01 00:00:00

  • Hemodynamic Effects, Safety, and Feasibility of Intravenous Esmolol Infusion During Takotsubo Cardiomyopathy With Left Ventricular Outflow Tract Obstruction: Results From A Multicenter Registry.

    abstract:BACKGROUND:Left ventricular outflow tract obstruction (LVOTO) may complicate an episode of Takotsubo cardiomyopathy (TTC), potentially leading to cardiogenic shock. Beta-blockers are considered the most suitable treatment for such complication. AIM OF THE STUDY:The objective of this study was to evaluate the hemodynam...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/1755-5922.12182

    authors: Santoro F,Ieva R,Ferraretti A,Fanelli M,Musaico F,Tarantino N,Martino LD,Gennaro LD,Caldarola P,Biase MD,Brunetti ND

    更新日期:2016-06-01 00:00:00

  • Insulin resistance: a potential new target for therapy in patients with heart failure.

    abstract::There is increasing evidence to suggest that chronic heart failure (CHF) is an insulin resistant (IR) state and that the degree of IR correlates with the severity and mortality of CHF. The pathophysiology of IR in CHF has yet to be fully defined. Additionally, it remains to be determined if IR is merely a marker refle...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2008.00053.x

    authors: Wong AK,AlZadjali MA,Choy AM,Lang CC

    更新日期:2008-10-01 00:00:00

  • Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release.

    abstract::Cilnidipine is a unique Ca(2+) channel blocker with an inhibitory action on the sympathetic N-type Ca(2+) channels, which is used for patients with hypertension in Japan. Cilnidipine has been clarified to exert antisympathetic actions in various examinations from cell to human levels, in contrast to classical Ca(2+) c...

    journal_title:Cardiovascular therapeutics

    pub_type: 历史文章,杂志文章,评审

    doi:10.1111/j.1755-5922.2009.00079.x

    authors: Takahara A

    更新日期:2009-07-01 00:00:00

  • Long Noncoding RNA TUG1 Promotes the Function in ox-LDL-Treated HA-VSMCs via miR-141-3p/ROR2 Axis.

    abstract:Background:Atherosclerosis (AS) is a common severe disease around the world. The merging paper reported that long noncoding RNAs (lncRNAs) took part in diversified pathological processes of AS, although the mechanism remains unknown. This study is aimed at uncovering the profile of lncRNA taurine-upregulated gene 1 (TU...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1155/2020/6758934

    authors: Tang Y,Hu J,Zhong Z,Liu Y,Wang Y

    更新日期:2020-05-29 00:00:00

  • Epac-Rap1-activated mesenchymal stem cells improve cardiac function in rat model of myocardial infarction.

    abstract:INTRODUCTION:Rap1, a member of Ras superfamily of small GTP-binding proteins, is involved in cardiovascular biology in numerous ways. It is an evolutionary conserved regulator of adhesion, polarity, differentiation and growth. AIMS:Our aim was to analyze Rap1-activated rat bone marrow mesenchymal stem cells (MSCs) for...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12248

    authors: Khan I,Ali A,Akhter MA,Naeem N,Chotani MA,Iqbal H,Kabir N,Atiq M,Salim A

    更新日期:2017-04-01 00:00:00

  • Warfarin persistence among atrial fibrillation patients - why is treatment ended?

    abstract:BACKGROUND AND AIM:Warfarin treatment discontinuation is significant among patients with atrial fibrillation (AF). Studies mainly focused on whether the proportion of warfarin persistence and discontinuation are clinically appropriate are absent. This study evaluates warfarin persistence with focus on predictors for, a...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12224

    authors: Björck F,Ek A,Johansson L,Själander A

    更新日期:2016-12-01 00:00:00

  • The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channel.

    abstract:BACKGROUND:The antianginal agent ranolazine (R) has shown some promise as an antiarrhythmic agent but its mechanism of action is not known. Previously, we have shown that R suppresses ventricular arrhythmias at a concentration >10 μM that may affect multiple ion currents including IKr. PURPOSE:The present study was ca...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1755-5922.2010.00203.x

    authors: Kloner RA,Dow JS,Bhandari A

    更新日期:2011-08-01 00:00:00

  • The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.

    abstract::Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long-term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alone or in combination...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/1755-5922.12083

    authors: Cohen M,Iyer D

    更新日期:2014-10-01 00:00:00

  • Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.

    abstract:INTRODUCTION:The effectiveness of statin pretreatment in reducing the incidence of contrast-induced nephropathy (CIN) has been examined in some observational and randomized studies, yielding controversial results. AIM:This study sought to evaluate the role of atorvastatin in prevention of CIN in diabetic patients with...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/1755-5922.12108

    authors: Shehata M,Hamza M

    更新日期:2015-04-01 00:00:00

  • Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans.

    abstract:INTRODUCTION:The metabolic modulator trimetazidine (TMZ) has been suggested to induce a metabolic shift from myocardial fatty acid oxidation (FAO) to glucose utilization, but this mechanism remains unproven in humans. The oxidation of plasma derived FA is commonly measured in humans, whereas the contribution of FA from...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1755-5922.2011.00275.x

    authors: Bucci M,Borra R,Någren K,Pärkkä JP,Del Ry S,Maggio R,Tuunanen H,Viljanen T,Cabiati M,Rigazio S,Taittonen M,Pagotto U,Parkkola R,Opie LH,Nuutila P,Knuuti J,Iozzo P

    更新日期:2012-12-01 00:00:00

  • Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study.

    abstract:BACKGROUND:Intracranial hemorrhage (ICH) is the most fearful side effect of oral anticoagulant therapy. It is still unclear which risk factor is involved in ICH during vitamin K antagonists (VKAs) treatment and if commonly used bleeding risk scores are able to predict ICH. PURPOSE:Search for individual risk factors an...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12458

    authors: Zanella L,Zoppellaro G,Marigo L,Denas G,Padayattil Jose S,Pengo V

    更新日期:2018-10-01 00:00:00

  • Pharmacological profile of the selective mitochondrial F1F0 ATP hydrolase inhibitor BMS-199264 in myocardial ischemia.

    abstract::The mitochondrial F1F0 ATP synthase is responsible for the majority of ATP production in mammals and does this through a rotary catalytic mechanism. Studies show that the F1F0 ATP synthase can switch to an ATP hydrolase, and this occurs under conditions seen during myocardial ischemia. This ATP hydrolysis causes wasti...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2008.00065.x

    authors: Grover GJ,Malm J

    更新日期:2008-01-01 00:00:00

  • What should medical practitioners know about the role of alternative medicines in cardiovascular disease management?

    abstract::Alternative medications as a term call up many different meanings, significance, and perceptions to various medical practitioners. Some are good; others are bad. A wide range of alternative medications with relevance or connection to cardiovascular (CV) disease have been considered. While many are worthless, others ha...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2009.00101.x

    authors: Whayne TF Jr

    更新日期:2010-04-01 00:00:00

  • Efficacy and safety of a second-generation biodegradable polymer sirolimus-eluting stent: One-year results of the CREDIT 2 trial.

    abstract:AIMS:We performed a multicenter, randomized controlled trial to determine the noninferiority of a novel biodegradable polymer drug-eluting stent (BP-DES), the EXCEL 2 stent, to the first-generation BP-DES, the EXCEL stent. METHODS AND RESULTS:Patients (n = 419) scheduled to undergo percutaneous coronary intervention (...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/1755-5922.12327

    authors: Xu K,Han Y,Xu B,Yang Y,Wang G,Li H,Sun Y,Tao L,Wang H,Yuan Z,Liu H,Liu J,Jia Y,Ma G,Fu G,Li X,Li S,Wang S,Pu K,CREDIT 2 Investigators.

    更新日期:2018-06-01 00:00:00

  • Fenoldopam in critically ill patients with early renal dysfunction. A crossover study.

    abstract:BACKGROUND:Acute kidney injury is a frequent problem among many critically ill patients, commonly in the context of multiple organ failure and decreased renal perfusion. Its presence conveys a poor prognosis. Currently, effective therapeutic interventions are limited and dopaminergic agonists have been suggested as an ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1755-5922.2010.00217.x

    authors: Cobas M,Paparcuri G,De La Pena M,Cudemus G,Barquist E,Varon A

    更新日期:2011-08-01 00:00:00

  • Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation.

    abstract:INTRODUCTION:Secondary pulmonary hypertension (PH) and right ventricular dysfunction are common and associated with poor prognosis in HF patients with left ventricular assist devices (LVADs). The role of pulmonary vasodilator therapy for these patients is currently unclear. AIMS:We sought to evaluate the safety and cl...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12111

    authors: LaRue SJ,Garcia-Cortes R,Nassif ME,Vader JM,Ray S,Ravichandran A,Rasalingham R,Silvestry SC,Ewald GA,Wang IW,Schilling JD

    更新日期:2015-04-01 00:00:00

  • Aspirin responsiveness changes in obese patients following bariatric surgery.

    abstract:AIMS:Bariatric surgery has emerged as a promising treatment option for weight loss and to counter the metabolic consequences of obesity. Obesity has been linked to a hyperaggregable state, as well as a blunted response to aspirin. This pilot study assessed the hypothesis that bariatric surgery would lead to an improvem...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12268

    authors: Norgard NB,Monte SV,Fernandez SF,Ma Q

    更新日期:2017-08-01 00:00:00

  • Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae Spirulina.

    abstract::Spirulina is free-floating filamentous microalgae growing in alkaline water bodies. With its high nutritional value, Spirulina has been consumed as food for centuries in Central Africa. It is now widely used as nutraceutical food supplement worldwide. Recently, great attention and extensive studies have been devoted t...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00200.x

    authors: Deng R,Chow TJ

    更新日期:2010-08-01 00:00:00

  • TREK-1 K(+) channels in the cardiovascular system: their significance and potential as a therapeutic target.

    abstract::Potassium (K(+) ) channels are important in cardiovascular disease both as drug targets and as a cause of underlying pathology. Voltage-dependent K(+) (K(V) ) channels are inhibited by the class III antiarrhythmic agents. Certain vasodilators work by opening K(+) channels in vascular smooth muscle cells (VSMCs), and...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00227.x

    authors: Goonetilleke L,Quayle J

    更新日期:2012-02-01 00:00:00

  • The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.

    abstract:AIM:Data evaluating the complications of pulmonary vein isolation (PVI) using second-generation cryoballoons (CB) related to different anticoagulation regimes are limited. This study evaluates the total complications and the impact of novel oral anticoagulants (NOACs) compared to phenprocoumon on adverse events in the ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12178

    authors: Koektuerk B,Turan CH,Yorgun H,Keskin K,Schoett M,Dahmen A,Gorr E,Yang A,Hoppe C,Horlitz M,Turan RG

    更新日期:2016-06-01 00:00:00

  • Cell-based therapy for chronic ischemic heart disease--a clinical perspective.

    abstract::In patients with ischemic heart disease, the goal of cell therapy is to improve perfusion and function of the damaged heart muscle. For this review, we selected articles that reported the findings from the major clinical studies of cardiovascular stem cell therapy in patients with chronic ischemic heart disease. Becau...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00214.x

    authors: Perin EC,Silva GV

    更新日期:2011-06-01 00:00:00

  • Aspirin resistance and compliance with therapy.

    abstract:INTRODUCTION:Aspirin resistance is associated with increased cardiovascular risk in aspirin-treated patients. Poor compliance may explain many cases of "resistance," yet few clinical studies have used objective measurement of therapy compliance. We did so in a case-controlled study. METHODS:We enrolled patients within...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1755-5922.2010.00188.x

    authors: Dawson J,Quinn T,Rafferty M,Higgins P,Ray G,Lees KR,Walters MR

    更新日期:2011-10-01 00:00:00

  • Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.

    abstract::Accelerated atherosclerosis and microvascular complications are the leading causes of coronary heart disease, stroke, blindness, and end-stage renal failure, which could account for disabilities and high mortality rates in patients with diabetes. Recent clinical studies have substantiated the concept of "hyperglycemic...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1527-3466.2007.00038.x

    authors: Yamagishi S,Nakamura K,Matsui T,Ueda S,Noda Y,Imaizumi T

    更新日期:2008-04-01 00:00:00

  • Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects.

    abstract:OBJECTIVES:Endothelial progenitor cells (EPCs) have been shown to participate in the process of vascular repair, thus playing a protective role against cardiovascular disease (CVD). It is known that atherosclerotic risk factors could affect EPC number and function. Advanced glycation end products (AGEs) contribute to t...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1755-5922.2011.00264.x

    authors: Ueda S,Yamagishi S,Matsui T,Noda Y,Ueda S,Jinnouchi Y,Sasaki K,Takeuchi M,Imaizumi T

    更新日期:2012-08-01 00:00:00

  • Iron deficiency in heart failure: Efficacy and safety of intravenous iron therapy.

    abstract:AIM:To discuss the pathophysiology of iron metabolism in chronic heart failure (CHF) and the current knowledge of the efficacy of intravenous (IV) iron therapy in patients with CHF and identify points of controversy as well as highlight areas for future research. DISCUSSION:Iron deficiency is a recognized complication...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/1755-5922.12301

    authors: Kang CK,Pope M,Lang CC,Kalra PR

    更新日期:2017-12-01 00:00:00

  • Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.

    abstract:INTRODUCTION:In two, 6-month, randomized, double-blind Phase 3 trials, PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) compared to aspirin alone was associated with fewer endoscopic gastric and duodenal ulcers in patients requiring aspirin therapy for secondary cardiovascular disease (CVD...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12172

    authors: Goldstein JL,Whellan DJ,Scheiman JM,Cryer BL,Eisen GM,Lanas A,Fort JG

    更新日期:2016-04-01 00:00:00

  • Prescribers' practice of assessing arrhythmia risk with QT-prolonging medications.

    abstract:AIMS:This study aimed to assess prescribers' monitoring for arrhythmic risk with QT-prolonging medications (LQT drugs). METHODS:Over a 6-month period, all inpatients under the care of Cardiologists (Cohort A) and General Physicians (Cohort B) at Aberdeen Royal Infirmary who were prescribed drugs with known risk of Tor...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12085

    authors: Choo WK,Turpie D,Milne K,Davidson L,Elofuke P,Whitfield J,Broadhurst P

    更新日期:2014-10-01 00:00:00

  • Treatment of pericardial disease.

    abstract::The pericardium is composed of visceral and parietal components. In view of the pericardium's simple structure, pathologic processes involving it are understandably few. However, despite a limited number of clinical syndromes, the pericardium is affected by virtually every category of disease, including infectious, ne...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00151.x

    authors: Azam S,Hoit BD

    更新日期:2011-10-01 00:00:00

  • Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials.

    abstract:Objective:The drug efficacy may differ among different statins, and evidence from head-to-head comparisons is sparse and inconsistent. The study is aimed at comparing the lipid-lowering/increasing effects of 7 different statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus by conducting s...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1155/2020/3987065

    authors: Zhang X,Xing L,Jia X,Pang X,Xiang Q,Zhao X,Ma L,Liu Z,Hu K,Wang Z,Cui Y

    更新日期:2020-04-23 00:00:00